Search Results - jennifer+maynard

9 Results

Sort By:

Engineered T-cell receptor platforms for targeted detection and treatment of cytomegalovirus-infected cells

This technology uses highly engineered T-cell receptors to precisely detect and target cytomegalovirus-infected cells, offering improved therapies and diagnostics by enhancing binding strength, stability, and resistance to viral immune evasion. Background Cytomegalovirus (CMV) is a widespread herpesvirus that poses significant health risks, particularly...

Published: 2/26/2026 | Inventor(s): Jennifer Maynard, Ellen Wagner, Ahlam Qerqez, Annalee Nguyen

Keywords(s):

Category(s): Life sciences > Immunology, Life sciences > Therapeutics

Anti-CD160 Humanized Antibody

Engineered humanized anti-CD160 antibodies and derivatives for depleting CD160+ immune cells to attenuate inflammation Background: Adaptive immune responses contribute significantly to the progression of acute myocarditis, where overactivation of cytotoxic lymphocytes leads to myocardial injury and eventual heart failure. Targeting immune receptors...

Published: 2/17/2026 | Inventor(s): Jennifer Maynard, Agata Turula

Keywords(s):

Category(s): Life sciences, Life sciences > Therapeutics > Biologic

Dual-target antibody toolkit for overcoming resistance in anti-angiogenic cancer therapy

Background Angiogenesis is a fundamental process in cancer progression, enabling tumors to grow and metastasize by forming new blood vessels. Vascular endothelial growth factor A (VEGFA) is a central driver of this process and a primary target for existing anti-angiogenic therapies. However, clinical resistance often develops through the compensatory...

Published: 1/27/2026 | Inventor(s): Jennifer Maynard, Samuel Blackman, Ahlam Qerqez, Nicole Johnson, Annalee Nguyen, Alison Lee

Keywords(s):

Category(s): Life sciences > Immunology, Life sciences > Research tools > Reagent

Engineered antibodies for enhanced immune response

Recombinant antibodies with engineered human IgG1 Fc domains have been developed to resist viral Fc receptor capture, enhancing immune targeting of virus-infected cells. These antibodies maintain normal host receptor affinity, potentially improving therapeutic outcomes against HCMV and related viruses. Background Human cytomegalovirus (HCMV) infection...

Published: 1/13/2026 | Inventor(s): Jennifer Maynard, Ahlam Qerqez, Alison Lee, Sumit Pareek

Keywords(s):

Category(s): Life sciences > Immunology

Monoclonal antibodies for the conserved feature of the coronavirus spike protein

The invention describes monoclonal antibodies targeting conserved epitopes on the S2 domain of coronavirus spike proteins, potentially useful for preventing or treating infections by inhibiting viral entry. These antibodies could aid in therapeutic formulations against coronaviruses like SARS-CoV-2, SARS-CoV, and MERS-CoV. Background The emergence...

Published: 3/2/2026 | Inventor(s): Jennifer Maynard, Yimin Huang, Annalee Nguyen, Ching-Lin Hsieh, Jason McLellan, Eduardo Padlan

Keywords(s):

Category(s): Life sciences > Immunology, Life sciences > Therapeutics > Vaccines

Engineered polypeptides for enhanced integrin binding and antigen delivery

Engineered recombinant Invasin polypeptides have been modified to enhance integrin binding and resist intestinal proteolysis, facilitating effective oral delivery of therapeutics, such as vaccines, by targeting M cells in the gut for improved immune responses. Background The challenge of delivering therapeutics such as vaccines effectively across...

Published: 1/13/2026 | Inventor(s): Jennifer Maynard, Xianzhe Wang, Tarik Khan

Keywords(s):

Category(s): Life sciences > Therapeutics > Vaccines, Life sciences > Agriculture > Animal/veterinary, Life sciences > Therapeutics > Drug delivery

Dual-target defense: bispecific antibodies revolutionize pertussis toxin neutralization

Bispecific antibodies target two epitopes on the pertussis toxin protein, enhancing toxin neutralization. Engineered using “knobs-into-holes” technology, they form stable heterodimers, offering similar efficacy to antibody mixtures but with streamlined manufacturing and regulatory benefits. Background Pertussis, or whooping cough,...

Published: 1/13/2026 | Inventor(s): Jennifer Maynard, Ellen Wagner

Keywords(s):

Category(s): Life sciences > Therapeutics > Gene therapy, Life sciences > Immunology

Treating respiratory diseases and whooping cough

This technology involves compositions and methods for treating respiratory diseases like whooping cough and includes immunization techniques. Background The field of respiratory disease treatment and immunization is important due to the significant health burden posed by conditions such as whooping cough. Whooping cough, or pertussis, is a highly...

Published: 1/13/2026 | Inventor(s): Jennifer Maynard, Jamie Sutherland, Matthew Croughan

Keywords(s):

Category(s): Life sciences > Therapeutics > Vaccines, Life sciences > Immunology

Innovative pH-selective antibody engineering for cancer therapy

Background Antibody-based cancer therapies have demonstrated impressive specificity but can lead to adverse effects by targeting antigens present on healthy cells. The acidic tumor microenvironment presents an opportunity for the development of antibodies with heightened tumor specificity through pH-dependent binding interactions. Technology...

Published: 1/13/2026 | Inventor(s): Jennifer Maynard, Yutong Liu, Annalee Nguyen

Keywords(s):

Category(s): Life sciences > Immunology